跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 757 条关于
“Arch Biopartners”
全部
757
临床试验
537
药物
70
机构
11
资讯
139
去年
Arch Biopartners Establishes Australian Subsidiary for Metablok Phase I Trial in Acute Kidney Injury
去年
Arch Biopartners Initiates Phase II Trial of LSALT Peptide for Cardiac Surgery-Associated Acute Kidney Injury
10个月前
Arch Biopartners Secures $600,000 CAD to Advance Kidney Disease Drug Development
去年
Arch Biopartners Acquires Novel IL-32 Platform for Chronic Kidney Disease Treatment
去年
Arch Biopartners Doses First Canadian Subject in Phase II Trial of LSALT Peptide for Cardiac Surgery-Associated Acute Kidney Injury
2年前
Arch Biopartners' LSALT Peptide Phase II Trial for Cardiac Surgery-Associated Acute Kidney Injury Approved in Turkey
2年前
Arch Biopartners Receives Ethics Approval for Phase II Trial of LSALT Peptide in Calgary
2年前
Arch Biopartners' LSALT Peptide Phase II Trial Approved for Cardiac Surgery-Associated Acute Kidney Injury
去年
Arch Biopartners Advances AKI Programs: LSALT Peptide and Cilastatin Trials Progress
去年
Arch Biopartners Doses First Patient in Phase II Trial for Cardiac Surgery-Associated Acute Kidney Injury
第 1 页,共 14 页
上一页
下一页